Drug Profile
Research programme: fructose biphosphatase inhibitors - Viking Therapeutics
Alternative Names: FBPase inhibitors - Viking TherapeuticsLatest Information Update: 17 May 2017
Price :
$50
*
At a glance
- Originator Ligand Pharmaceuticals
- Developer Viking Therapeutics
- Class Small molecules
- Mechanism of Action Fructose bisphosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Type 2 diabetes mellitus